Published in J Urol on May 01, 1982
Squamous and transitional elements in rat bladder carcinomas induced by N-butyl-N-4-hydroxybutyl-nitrosamine (BBN). A study of cytokeratin expression. Am J Pathol (1985) 0.95
Clinicopathological importance of primary dysplasia of bladder. J Clin Pathol (1988) 0.86
High expression level of BLCA-4 correlates with poor prognosis in human bladder cancer. Int J Clin Exp Pathol (2012) 0.82
Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol (1992) 4.79
Quality of life: radical prostatectomy versus radiation therapy for prostate cancer. J Urol (1995) 2.80
Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol (1998) 1.88
Small cell carcinoma of the bladder and prostate. Urology (1995) 1.81
Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol (1995) 1.71
De novo muscle invasive bladder cancer: is there a change in trend? J Urol (2001) 1.54
Sampling of radical prostatectomy specimens. How much is adequate? Am J Clin Pathol (1994) 1.51
Prostatectomy tissue for research: balancing patient care and discovery. Am J Clin Pathol (1998) 1.48
Transitional cell carcinoma of the prostate. J Urol (1991) 1.47
The accuracy of urinary cytology in daily practice. Cancer (1999) 1.46
Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. Cancer (1992) 1.44
Positive surgical margins with radical retropubic prostatectomy: anatomic site-specific pathologic analysis and impact on prognosis. Urology (1999) 1.44
Academic anatomic pathology--a perspective. Mod Pathol (1996) 1.38
Does pericapsular lignocaine reduce pain during transrectal ultrasonography-guided biopsy of the prostate? BJU Int (2003) 1.38
Patients' choice of treatment in stage D prostate cancer. Urology (1989) 1.34
Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients. Cancer (1995) 1.34
Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation. Cancer (1994) 1.33
Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res (1997) 1.28
The histogenesis of clear cell adenocarcinoma of the lower urinary tract. Case series and review of the literature. Hum Pathol (1996) 1.26
Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology (1995) 1.23
Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol (2000) 1.22
Urinary cytology and bladder cancer. The cellular features of transitional cell neoplasms. Cancer (1984) 1.21
Rationale for intensive intravesical chemotherapy for superficial bladder cancer. J Urol (1980) 1.21
Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen. J Urol (1999) 1.18
Positive surgical margins with radical prostatectomy: detailed pathological analysis and prognosis. Urology (1996) 1.18
Update on bladder neck preservation during radical retropubic prostatectomy: impact on pathologic outcome, anastomotic strictures, and continence. Urology (1998) 1.17
Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer (1980) 1.15
Complications of advanced prostate cancer. Urology (1999) 1.13
Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of >/=8. BJU Int (2003) 1.13
Local anesthesia for ultrasound guided prostate biopsy: a prospective randomized trial comparing 2 methods. J Urol (2001) 1.09
Phase I-II study of mitomycin C topical therapy for low-grade, low stage transitional cell carcinoma of the bladder: an interim report. Cancer Treat Rep (1980) 1.09
Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer (1991) 1.08
The nested variant of transitional cell carcinoma: an aggressive neoplasm with innocuous histology. Mod Pathol (1996) 1.08
Intravesical and systemic chemotherapy of murine bladder cancer. Cancer Res (1977) 1.07
Ileal conduit exfoliative cytology in the diagnosis of recurrent cancer. J Urol (1972) 1.05
Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer (1983) 1.04
The effect of mitomycin C on superficial bladder cancer. J Urol (1981) 1.03
Quality of life 12 months after radical prostatectomy. Br J Urol (1995) 1.02
Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer. J Urol (2000) 1.01
Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology (1997) 1.00
Renal disease after mitomycin C therapy. Cancer (1981) 1.00
Bond strength and rupture properties of some soft denture liners. J Oral Rehabil (1992) 0.99
Current bladder tumor tests: does their projected utility fulfill clinical necessity? J Urol (2001) 0.98
Prostate cancer after heart transplantation. J Urol (1995) 0.97
The significance of colonic mucosa (intestinal metaplasia) involving the urinary tract. Cancer (1987) 0.97
Classification of premalignant urothelial abnormalities. A Delphi study of the National Bladder Cancer Collaborative Group A. Pathol Annu (1982) 0.97
Susceptibility of urothelium to neoplastic cellular implantation. Urology (1975) 0.96
Myocarditis in young military personnel. Herpes simplex, trichinosis, meningococcemia, carbon tetrachloride, and idiopathic fibrous and giant cell types. Am Heart J (1967) 0.96
Papillomavirus structural antigens in condyloma acuminatum of the male urethra. J Urol (1983) 0.96
The pains of love: hemoperitoneum following sexual intercourse. JAMA (1986) 0.96
Selecting initial therapy for bladder cancer. Cancer (1987) 0.95
Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA (1987) 0.95
A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A National Bladder Cancer Collaborative Group A Study. Cancer (1983) 0.94
Transitional cell neoplasms of the urinary bladder. Can biologic potential be predicted from histologic grading? Cancer (1987) 0.94
Signet ring cell carcinoma of a pulled-through sigmoid colon mimicking a primary invasive bladder tumor: case report and review of the literature. Urology (2000) 0.94
Active surveillance for low-risk prostate cancer: knowledge, acceptance and practice among urologists. Prostate Cancer Prostatic Dis (2011) 0.94
Prophylaxis of bladder tumor implantation. Intravesical and systemic chemotherapy. Urology (1976) 0.93
Carcinoma of the rete testis: case report and review of the literature. J Urol (1993) 0.92
Epithelioid leiomyoma of the bladder: an unusual cause of voiding symptoms. Urology (1998) 0.92
Histopathological effects of androgen deprivation in prostatic cancer. Semin Urol Oncol (1996) 0.92
Immunohistochemical evidence of the existence and localization of aromatase in human prostatic tissues. Prostate (1992) 0.92
Cytology in the diagnosis and followup of transitional cell carcinoma of the urothelium: a review with a case series. J Urol (1976) 0.92
Comparison of goserelin and leuprolide in combined androgen blockade therapy. Urology (1998) 0.91
The use of cell salvage during radical retropubic prostatectomy: does it influence cancer recurrence? BJU Int (2003) 0.91
Prognostic significance of urine cytology on initial follow-up after intravesical mitomycin C for superficial bladder cancer. Cancer (1986) 0.90
Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group. Qual Life Res (1992) 0.90
Finite element analysis of fixed prostheses attached to osseointegrated implants. Quintessence Int (1990) 0.90
IgA nephropathy. A comparative study of the clinicopathologic features in children and adults. Am J Clin Pathol (1985) 0.89
Early prostate cancer: prevention, treatment modalities, and quality of life issues. Eur Urol (2003) 0.89
Regional lymphadenectomy and tumor immunity. Surg Gynecol Obstet (1976) 0.89
Side effects associated with intravesical mitomycin. J Urol (1981) 0.89
Radical cystectomy and adjuvant chemotherapy. Urology (1985) 0.89
Cis-diamminedichloroplatinum II in advanced urothelial cancer. J Urol (1978) 0.89
Bladder neck preservation following radical prostatectomy: continence and margins. Eur Urol (1995) 0.89
Cis-diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancer. Cancer (1981) 0.89
Urothelial susceptibility to tumor cell implantation: comparison of cauterization with N-methyl-N-nitrosourea. Urology (1983) 0.88
Carcinoma in situ of the urinary bladder. Clues to host involvement in human carcinogenesis. Cancer (1994) 0.88
Aspiration biopsy of the kidney. Simultaneous collection of cytologic and histologic specimens. Cancer (1985) 0.88
Squamous cell carcinoma of the prostate: a transformation from adenocarcinoma after the use of a luteinizing hormone-releasing hormone agonist and flutamide. Urology (1995) 0.87
Elevated tissue expression of hyaluronic acid and hyaluronidase validates the HA-HAase urine test for bladder cancer. J Urol (2001) 0.87
Serial multiple-site biopsies in patients with bladder cancer. J Urol (1978) 0.86
Overview of treatment of superficial bladder cancer. Urology (1985) 0.86
Comparison of urologist reimbursement for managing patients with low-risk prostate cancer by active surveillance versus total prostatectomy. Prostate Cancer Prostatic Dis (2010) 0.86
Developing carcinoma (dysplasia) of the urinary bladder. Pathol Annu (1982) 0.86
Fibroepithelial polyp of the renal pelvis: nephron-sparing surgery after false-positive biopsy for transitional cell carcinoma. Urology (1997) 0.85
Value of urine cytology versus bladder washing in bladder cancer. Urology (1992) 0.85
Morphologic effects of thio-TEPA on mammalian urothelium. Changes in abnormal cells. Acta Cytol (1979) 0.85
Modified Pfannenstiel approach for radical retropubic prostatectomy: a 3-year experience. Prostate Cancer Prostatic Dis (2007) 0.85
Hemospermia following transrectal ultrasound-guided prostate biopsy: a prospective study. Prostate Cancer Prostatic Dis (2007) 0.85
In vitro characterization of four N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT) induced mouse bladder tumors. J Urol (1982) 0.84